Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid Therapy. Extension of the Study Beyond Three Years.

Pfizer Inc0 个研究点目标入组 21 人开始时间: 2015年4月1日最近更新: 2015年4月7日

适应症

试验速览

暂无简介。

•1.All subjects had to be previously included in Study CTN 97-8129-016 to continue somatropin treatment until FH was reached.
•2.All subjects should have received corticosteroid therapy, whatever the dose or the method of administration.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 21
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Discontinuation of corticosteroid therapy for more than a year during Study CTN 97-8129-016.
•2.Concomitant severe, chronic disease: renal failure (glomerular filtration less than or equal to [<=] 50 mililiter per min per meter [ml/mn/1m] ^2 73), nephrotic syndrome, hepatic failure, diabetes.
•3.Endocrine disorder except for adequately compensated hypothyroidism.
•4.Subjects withdrawing from the study prematurely.
•5.Non-compliant subjects.
•6.Inclusion in another protocol.

发起方